A comprehensive pan-cancer multi-omics analysis identifies CDKN2A as a promising biomarker associated with clinical outcomes and immune infiltration.
文献摘要
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, a critical regulator of cell cycle progression, has been widely implicated in the pathogenesis of various malignancies; however, its comprehensive functional profile across diverse tumor types remains to be fully elucidated. This study aims to comprehensively characterize the pan-cancer expression landscape of CDKN2A and elucidate its associations with clinical outcomes, tumor immune infiltration, and underlying biological functions. Our findings reveal that dysregulated CDKN2A expression is significantly associated with OS, DSS, and PFI in several cancers. Notably, CDKN2A expression correlates with distinct clinicopathological characteristics in six tumor types. Moreover, CDKN2A is closely linked to the tumor immune infiltration and displays frequent somatic mutations and promoter methylation across multiple cancers, contributing to adverse clinical outcomes. In conclusion, this study highlights the differential expression of CDKN2A across human cancers and its significant association with clinical prognosis. CDKN2A shows promise as both a prognostic biomarker and a potential therapeutic target in specific malignancies. Furthermore, its involvement in modulating the tumor immune infiltration suggests a role in anti-tumor immunity. These results provide novel insights into the biological functions of CDKN2A in tumorigenesis and advance our understanding of its translational relevance in oncology.